Market Overview

UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results

Share:
Related PCRX
Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
Aratana Therapeutics Announces Positive Pivotal Results for AT-003

In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target from $86.00 to $104.00.

In the report, Bank of America noted, “We are raising our PO to $104 (from $86) based on positive results from our Exparel survey, including a meaningful change in the outlook from anesthesiologists and expectations for significant revenue growth. We see upside from use in the nerve block indication (March 5, 2015 PDUFA date) as anesthesiologists in our survey stated they would use Exparel in roughly half of their nerve block procedures if approved.

"We modestly adjusted our peak market share in nerve block to 25% (from 20%) and increased our 2021 peak sales to $2.3bn (from $2.1bn), which assumes some IP extension potential (spray based technology would extend IP to 2031) and expansion of PCRX' manufacturing capacity (readily replicable in our view). We see upside from other DepoFoam–derived products such as NSAIDs.”

Pacira Pharmaceuticals closed on Wednesday at $85.14.

Latest Ratings for PCRX

DateFirmActionFromTo
Jul 2015JefferiesMaintainsBuy
Jun 2015Leerink SwannInitiates Coverage onMarket Perform
May 2015Canaccord GenuityMaintainsBuy

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Bank of America Steve ByrneAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

Get Benzinga's Newsletters